"They've done such a miserable job these last two years, I think they should leave! Not get bonuses of $40,000 [to] $50,000!" Rep. Bart Stupak, D-Mich., said. "Good grief."
"What we are talking about here is the need to have highly experienced, highly capable technical experts that, without which, the country would suffer," said FDA Commissioner Andrew von Eschenbach.
"These should be referred to not as retention bonuses but blackmail bonuses," said Tom Schatz, president of Citizens Against Government Waste.
All this has not gone unnoticed by Emily, the intern at FDA, as we document in this installment of FDA INTERN!
Yes, it's FDA Intern! Strange visitor from an Ivy League school who came to FDA with powers and ability far beyond those of Janet Woodcock or even FDA commish Andy von Eschenbach!FDA Intern! Who can change the course of mighty clinical trials, approve drug ads faster than a speeding bullet, jump through Congressional Subcommittee hoops of fire and ire, and who disguised as Emily Jameson (no relation to Jenna Jameson), mild-mannered intern for a great regulatory agency, fights a never ending battle for fast-track drug approvals, pharmaceutical company user fees, and the FDA way!
As if the FDA didn't have enough naysayers, now the public is learning that compensation of FDA officials has been inflated. Tomatoes, longer drug review times, understaffing, and an absentee Commissioner...now this.
ReplyDeleteIronically, Beaker was just present at the BIO 2008 Career Fair. Want to guess the booth with the largest crowd. Nope, not Invitrogen, Amgen or Genentech. You guessed it. The candidates were swarming to the booth hosted by the FDA.
In a down market, industry stock options are worthless & cash is king. So, with visions of inflated bonuses in their minds, I understand why young job seekers are so smitten.